Could a lower dose of this thyroid cancer drug be just as good?

NCT ID NCT07092514

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two doses of the drug lenvatinib (24 mg vs 10 mg daily) in 34 people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if the lower dose causes fewer side effects while still controlling the cancer. Participants take the drug by mouth and are monitored for tumor response and treatment tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib (Lenvima)
What this could lead to: If successful, this could show that a lower dose of lenvatinib is as effective but with fewer side effects, improving quality of life for patients with advanced thyroid cancer.
What could go wrong: This is a small, early-phase trial with only 34 participants, so results may not apply broadly. The lower dose might be less effective at controlling the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF THE THYROID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma thyroid cancer thyroid gland carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF THE THYROID THYROID CANCER

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.